The chemical class known as FGF-8F activators encompasses a variety of compounds that can influence the modulation of the FGF-8F protein's activity through their interaction with several cellular signaling pathways. These activators are primarily characterized by their ability to interfere with the intracellular signaling cascades that FGF-8F is known to be involved in, such as the MAPK, PI3K/AKT, and PLCγ pathways. The actions of these chemicals result in cellular responses that can lead to the activation of FGF-8F signaling, albeit in an indirect fashion, by triggering a complex network of regulatory mechanisms within the cell.
The chemical activators in this class typically function by inhibiting specific enzymes or kinases that are crucial components of the signaling pathways related to FGF-8F activity. This inhibition can result in the alteration of the cellular signaling environment, which can, in turn, trigger compensatory responses that activate FGF-8F signaling. These responses may include the upregulation of other signaling molecules, alteration of receptor sensitivities, or changes in the expression levels of various downstream targets. By affecting these pathways, the activators can influence the cellular processes that are governed by FGF-8F, such as cell proliferation, differentiation, and survival. The diversity of these compounds allows for the modulation of FGF-8F signaling in multiple contexts, reflecting the broad biological roles that FGF-8F plays in cellular function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A selective inhibitor of MEK, a kinase in the MAPK pathway; by inhibiting MEK, U0126 can lead to compensatory mechanisms that could activate FGF8 signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that disrupts downstream AKT signaling, which can impact FGF8 activity through cellular signaling feedback loops. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor, which can alter AKT pathway signaling and could activate FGF8 signaling through changes in cellular homeostasis. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A selective inhibitor of MEK1/2 in the MAPK pathway; by blocking this pathway, PD98059 can modify the cellular context in a way that could activate FGF8 signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor which affects PI3K/AKT signaling and could activate FGF8 signaling by initiating compensatory cellular responses. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that can modify the MAPK pathway, potentially altering the cellular environment in a manner that could activate FGF8 signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which is part of the MAPK pathway; this modification of stress response pathways could activate FGF8 signaling. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor that influences cytoskeleton dynamics and could activate FGF8 signaling through changes in cellular architecture. | ||||||
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
An inhibitor of MEK, which by altering MAPK signaling, could activate the regulation of FGF8. | ||||||
GSK 2334470 | 1227911-45-6 | sc-364501 sc-364501A | 10 mg 50 mg | $199.00 $1165.00 | 1 | |
A specific inhibitor of PDK1, a kinase upstream of AKT; by modifying AKT signaling, it could activate FGF8 signaling. | ||||||